Mark Lebwohl
Icahn School of Medicine, Mount Sinai, New York, NY
Linda Stein Gold
Henry Ford Health System, Detroit, MI
Bruce Strober
Yale University, New Haven and Central Connecticut Dermatology Research, Cromwell, CT
April Armstrong
Keck School of Medicine University of Southern California, Los Angeles, CA
H Chih-Ho Hong
University of British Columbia and Probity Medical Research, Surrey, BC, Canada
Leon Kircik
Icahn School of Medicine, Mount Sinai, New York, NY; Skin Sciences, PLLC, Louisville, KY
Jennifer Soung
Southern California Dermatology, Santa Ana, CA
Jeff Fromowitz
Dermatology of Boca, Boca Raton, FL
Scott Guenthner
The Indiana Clinical Trials Center, PC, Plainfield, IN
Stephen Piscitelli
Dermavant Sciences, Inc., Durham, NC
David Rubenstein
Dermavant Sciences, Inc., Durham, NC
Philip Brown
Dermavant Sciences, Inc., Durham, NC
Anna Tallman
Dermavant Sciences, Inc., Durham, NC
Robert Bissonnette
Innovaderm Research Inc., Montreal, QC, Canada
Keywords
Psoriasis, Aryl Hydrocarbon Receptor Modulating Agent, Tapinarof, Safety, Efficacy
References
1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850
2. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721
3. Stein Gold L, et al. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.04.181.